Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This study will be conducted retrospectively (for patients who had their first treatment initiated on either Ofatumumab or Ocrelizumab before study start and from 2019 onwards) and prospectively (for patients who are initiated on either drug during the active recruitment period which spans for one year after the start of the first data collection) using data collected in a standardized manner.
Index date (baseline): Defined as the date of the first treatment initiated on either Ofatumumab or Ocrelizumab Index period: The patients fulfilling the inclusion criteria will be identified during the recruitment period (01-Jan-2019 to 01-April-2023 or up to 1 year after the start of the active recruitment period).
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and Females.
Age 18 to 65 years.
Confirmed RMS diagnosis as per the 2017 updated McDonald's criteria (Thompson et al., 2018).
Having their first dose of either drugs during the index period (2019 onwards and up to 1 year since start of the active recruitment period).
The decision to initiate either drug should be based on the patient's disease and taken by the treating physician before the decision of inviting the patient to participate in the study.
The patient agreed and provided informed consent on the use of his/her de-identified data.
You may not be if
Patients below 18 years or above 65 years.
Pregnant females.
SPMS and/or PPMS patients.
The patient's refusal to be included in the study.
Clareo Health | Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
